A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-10
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Status changed from active, no longer recruiting to completed.
- 25 Jan 2017 This trial has been completed in Spain.